Ophthalmology News

CHICAGO — In this Healio Video Perspective from the AAO meeting, George O. Waring IV, MD, FACS, presents 9-month clinical data on the Teneo laser from Bausch + Lomb for the treatment of myopia and myopic astigmatism with LASIK.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Daniel H. Chang, MD, of Empire Eye and Laser Center discusses his Refractive Surgery Subspecialty Day presentation on the categories of presbyopia-correcting IOLs.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Matthew Giegengack, MD, of Wake Forest University discusses the outcomes of corneal endothelial cell therapy for endothelial dysfunction.

LAS VEGAS — Visionix introduced the VX 610 nonmydriatic automated fundus camera to attendees at Vision Expo West.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Nordic Pharma Eye Care U.S. president Philip Gioia and chief commercial officer Jai G. Parekh, MD, MBA, FAAO, discuss Lacrifill’s launch and its impact on dry eye treatment.

EyePoint Pharmaceuticals announced that the first patient has been dosed in the global, phase 3 LUGANO clinical trial of Duravyu, formerly EYP-1901, as a treatment for wet age-related macular degeneration, according to a press release.

BARCELONA, Spain — A large amount of real-world data collected from clinics across the U.K. highlighted the effectiveness, safety and durability of faricimab for diabetic macular edema in treatment-naive and previously treated eyes.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Jennifer M. Loh, MD, shares results from the NEAR phase 3 clinical trials, which investigated Qlosi, a low-dose pilocarpine eye drop for the treatment of presbyopia.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Uday Devgan, MD, of Devgan Eye Surgery recommends the ZeptoLink device for avoiding Argentinian flag sign in patients with white cataracts.

CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.